ImmBio initiates First-in-Human study of PnuBioVax
11 December 2015 | By Victoria White
The study will look at the safety and tolerability of PnuBioVax for three different dosages against the bacterial pathogen Streptococcus pneumoniae...
List view / Grid view
11 December 2015 | By Victoria White
The study will look at the safety and tolerability of PnuBioVax for three different dosages against the bacterial pathogen Streptococcus pneumoniae...
11 December 2015 | By Victoria White
The companies have joined WCPR to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome...
10 December 2015 | By Victoria White
SRI Biosciences and physician-researchers from Stanford Cancer Institute (SCI) are to pursue development of novel compounds to treat multiple forms of cancer and other conditions...
10 December 2015 | By Victoria White
A team of scientists have tapped into publically available large-scale 'Omics' databases to identify new targets to treat influenza...
10 December 2015 | By Victoria White
The partnership will focus on using nanotechnologies based on Cour’s Tolerizing Immune Modifying nanoParticle (TIMP) platform...
9 December 2015 | By Victoria White
The gene therapy pipeline has more than 900 products in development, and the early-stage pipeline looks particularly strong with 76% of products at either the discovery or preclinical stage...
9 December 2015 | By Victoria White
Researchers at University of Florida have used gene therapy in a rat model to show that the expression of a particular receptor can reinstate lost memory function...
9 December 2015 | By Victoria White
The discovery, made by scientists from the Salk Institute, could help the millions of people worldwide affected by liver fibrosis and cirrhosis, caused by alcoholism and diseases like hepatitis...
9 December 2015 | By Victoria White
Researchers have identified the molecule, Tc24, that is expressed by Trypanosoma cruzi and may facilitate the parasite's evasion of the host's immune system...
8 December 2015 | By Victoria White
Doctors are harnessing patients’ own immune systems in a pioneering trial taking place in London in an effort to find a new effective treatment for resistant head and neck cancer...
8 December 2015 | By Victoria White
BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialisation of several CAB-ADC antibodies...
8 December 2015 | By Victoria White
VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate...
7 December 2015 | By Victoria White
Parkinson’s disease researchers at the University at Buffalo have developed a way to ramp up the conversion of skin cells into dopamine neurons...
7 December 2015 | By Victoria White
The €100m ENABLE project aims to identify at least three antibacterial lead molecules with promising antibacterial activity, two antibacterial clinical candidate molecules and to enter at least one compound into preclinical and Phase 1 clinical studies...
7 December 2015 | By Victoria White
The collaboration, facilitated by Johnson & Johnson Innovation, aims to develop new cyclophilin inhibitors for neurodegenerative diseases...